Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium animalis subsp. lactis NJ241
- Development stage
- Preclinical
- Lead developer
- Thankcome Biotechnology
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium animalis subsp. lactis NJ241 is a specific probiotic strain being researched for its neuroprotective potential in Parkinson's disease (PD). It operates through the microbiota-gut-brain axis, where it helps restore intestinal microbial balance and increases the production of short-chain fatty acids (SCFAs). Mechanistically, NJ241 elevates intestinal levels of glucagon-like peptide-1 (GLP-1), which in turn activates GLP-1 receptors (GLP-1R) and the PGC-1α signaling pathway in the substantia nigra. This pathway activation leads to reduced neuroinflammation, inhibition of glial cell activation, and protection of dopaminergic neurons from death, as demonstrated in MPTP-induced mouse models of PD.
- Other names
- Bifidobacterium animalis subsp. lactis NJ241NJ241NJ-241NJ 241
02
Targets
GLP1R (GLP-1R)PPARGC1A (Peroxisome proliferator–activated receptor gamma coactivator 1-alpha)
Beyond the preview
Go deeper on bifidobacterium animalis subsp. lactis NJ241.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium animalis subsp. lactis NJ241.